Introduction
Sleep apnoea (SA) occurs in 2-4% of the general population [1] . Obesity, male gender, congestive heart failure (CHF), cerebrovascular disease and neurodegenerative disorders are major risk factors for SA. SA syndrome is prominent among the many sequelae affecting chronic dialysis patients, and it is a recognized cause of cardiovascular disease. During episodes of SA, hypoxia triggers brisk sympathetic activation that may result in sympathetic overactivity and hypertension [2] . In chronic dialysis patients, SA frequency has been reported as high as 50% [3] . The reasons for this 10-to 20-fold higher SA prevalence in dialysis patients compared to the general population are not entirely clear. It has been speculated that uraemic toxins, overhydration and comorbidities such as hypertension and CHF may play essential roles [4] . This notion is supported by results from a recent study showing that SA is reversed in renal transplant recipients [5] . In this cross-sectional study, we aimed to test the hypothesis that CKD is more prevalent in patients with SA.
Methods

Study population
In this cross-sectional study, we investigated the prevalence of CKD in consecutive patients referred to standardized full night observed inhospital polysomnography for suspected SA. All patients referred between January 2004 and April 2007 in whom serum creatinine determinations were available within 4 weeks of polysomnography were enrolled in this study.
Prior to polysomnography, the patients answered standardized questionnaires, with the assistance of a physician, regarding their medication use (number and class of antihypertensive drugs; use of benzodiazepines; drugs for pharmacologic treatment of Parkinson's disease), sleep disturbances, snoring, subjective sleep quality, daytime fatigue, pre-existing illnesses and surgery.
Serum creatinine was determined with a standardized serum creatinine assay. Glomerular filtration rate (eGFR; expressed in mL/min/1.73 m 2 ) was calculated with the abbreviated MDRD equation [6] . The patients were stratified by eGFR into three groups: group 1 (eGFR ≥90); group 2 (eGFR 60-89) and group 3 with CKD stage 3 as defined by an eGFR between 30 and 59 mL/min/1.73 m 2 [7] . Since urinalysis was available only in a minority of patients, the presence or absence of CKD in patients in groups 1 and 2 was undetermined.
Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared.
Polysomnography
Polysomnography employed the Alice 4 system (Respironics Inc., Switzerland). Recordings included electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest and abdominal wall movement by inductance plethysmography. Airflow was measured with nasal and oral pressure transducer and capillary oxygen was measured by finger pulse oximetry.
Sleep stages were scored from 1 to 4 using the Rechtshaffen and Kales criteria [8] with arousals scored using the American Sleep Disorders Association (ASDA) criteria [9] . Hypopnoea was defined as a reduction of nasal pressure airflow of at least 10 s associated with a drop in oxygen saturation of ≥4% and/or arousal from sleep. Obstructive SA (OSA) was defined by the absence of nasal and oral airflow ≥10 s in the presence of thoracic and/or abdominal breathing efforts.
Central SA (CSA) was defined as the absence of nasal and oral airflow in combination with no evidence of both abdominal and thoracic breathing effort. Cheyne-Stokes breathing (CSB) with CSA was defined as a form of periodic breathing in which apnoeas and hypopnoeas alternate with prolonged ventilatory periods characterized by a cyclic crescendodecrescendo respiratory effort and airflow during wakefulness or sleep, without upper airway obstruction. The frequency of respiratory events was expressed as the number of events per hour.
The respiratory disturbance index (RDI) was defined by dividing the sum of central, obstructive and mixed apnoeas and hypopnoeas by the number of hours of sleep.
The arousal index was defined as the number of abrupt changes from sleep to wakefulness per hour. The desaturation index was defined as the occurrences of oxygen desaturation <85%/h.
Three experienced physicians masked to the patient's eGFR scored all polysomnography studies manually. A specifically trained nurse was present during the entire night of polysomnography recordings and interfered in the event of poor recording quality.
The study was approved by the local ethical committee of the Krankenhaus der Barmherzigen Brüder, Graz, Austria.
Statistical analysis
Continuous data were shown as mean ± standard deviation and 95% confidence interval. Frequencies were reported in absolute numbers and percentages. Polysomnography variables were compared between eGRF groups by univariate analysis of variance (ANOVA) with post hoc analysis and Bonferroni correction for multiple testing. Non-parametric tests were used in the case of absent normal distribution. Categorical variables were compared by the χ 2 test.
Multivariate analysis employed multiple linear regression analysis with polysomnography outcomes as dependent variables, and with the following independent parameters: eGFR (as a continuous variable) or CKD stage 3 (yes/no), age, gender, BMI, New York Heart Association (NYHA) class ≥3 (yes/no), current smoking status (yes/no), antihypertensive therapy (yes/no) and diabetes mellitus (yes/no). Independent variables were chosen based on their known or suspected association with SA. A two-sided P-value <0.05 was considered significant. Statistical analysis was done with SPSS version 11.5 (SPSS Inc.).
Results
The study period was between January 2004 and April 2007. In 162 consecutive patients referred for standardized full night observed in-hospital polysomnography for suspected SA, serum creatinine measurements in close temporal proximity to the sleep study (< 4 weeks) were available. Four patients, each with CKD stages 4 and 5, respectively, were excluded from the study, because they were referred for suspected SA based on advanced CKD. Subsequent analysis involved the remaining 158 subjects (92 males).
The mean (95% confidence interval) age was 61 years (59-61), BMI was 29. Table 1 . The patients with stage 3 CKD were significantly older. The prevalence of comorbidities (hypertension, diabetes, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease) did not differ between the three groups.
The fraction of patients with NYHA class ≥3 was significantly greater in CKD 3. The percentage of patients on beta-blockers and on diuretics was significantly higher in CKD 3. Also, the sum of antihypertensive drugs taken was significantly higher in CKD 3 (P = 0.032).
The polysomnography results are summarized in Table 2 and Figure 1 . The number of REM phases in group 2 and CKD 3 was significantly lower compared to group 1 (P = 0.005), but duration of REM phases did not differ. Although the number of sleeping stages 1-3 differed between the groups, the duration of the stages did not show any relationship with eGFR (data not shown).
The prevalence of SA, as defined by an RDI >5, did not differ between the three groups: 80% in group 1; 86% in group 2 and 94% in CKD 3 (P = 0.248). It is noteworthy that the type of SA differed significantly between the three groups ( Table 2 ). The number of CSA per hour was about six times greater in CKD 3 patients compared to patients with eGFR ≥ 60 mL/min/1.73 m 2 . CSA were more severe in CKD 3 patients as indicated by an ∼10-fold greater frequency of CSA with oxygen saturation drop ≥4% (Table 2) (both P < 0.0001). In CKD 3 patients, the number of CSA was increased during REM (P < 0.0001) and NREM (P = 0.001) phases (Table 2) . CSB with CSA was observed in 11 patients and was more frequent in CKD 3 (4 patients; 23.5% of patients with CSA) when compared to group 1 (1 patient; 1.8% of CSA) and group 2 (6 patients; 11.5% of CSA) (P = 0.014). eGFR was significantly reduced in patients with CSB compared to patients with other forms of CSA (69.1 ± 14.1 versus 86.8 ± 21.9 mL/ min/1.73 m 2 ; P = 0.01). Neither frequency nor severity of OSA differed between the three groups. Mixed apnoeas were more frequent in CKD 3 patients (P = 0.044). Hypopnoeas, desaturation CBS, Cheyne-Stokes breathing; pts, patients; RDI, respiratory disturbance index; TST, total sleeping time; data are expressed as mean (95% confidence interval). index and arousal index did not differ between the three groups.
Multivariate analysis
Multiple regression analysis was employed to model the number of CSA per hour as a function of gender, age (years), body mass index (BMI), current smoking status (yes/no), NYHA class ≥3 (yes/no), antihypertensive therapy (yes/no), eGFR (as a continuous variable; Table 3A) or CKD 3 (Table 3B ), respectively. NYHA class ≥3 and CKD 3 were the only statistically significant predictors of CSA events in a multiple regression model.
Discussion
The main finding of the study is a higher prevalence of CSA in stage 3 CKD patients when compared to patients with an eGFR ≥ 60 mL/min. This finding remains consistent after adjustment for comorbidities with a recognized association with CSA, in particular CHF. There exists a significant body of evidence showing that the prevalence of SA in patients undergoing maintenance haemodialysis (MHD) may be as high as 50% [3] . In contrast to the abundant literature on sleeping disorders in MHD [3, [10] [11] [12] [13] [14] [15] and peritoneal dialysis [16] , to the best of our knowledge, only two studies employing standardized full night observed in-hospital polysomnography in pre-dialysis CKD patients have been published to date [17, 18] . In both studies, CKD stage 4 and 5 patients have been investigated. Parker et al. [17] studied eight patients with CKD stage 4 or 5 (age 43.1 ± 11.8 years; mean eGFR 14.5 mL/min with a range from 5.4 to 28.8), all of whom were free from other significant physical and psychological morbidities. They compared the polysomnographic findings from these 8 patients to those from 16 MHD patients. The authors reported less rapid eye movement (REM) sleep and a higher brief arousal index in CKD patients. Markou et al. [18] investigated 35 nondialysis CKD patients, stage 4 or 5 (age 57.3 ± 12 years; mean eGFR 26.8 mL/min; range 11-40). Inclusion criteria in this study were age ≤70 years and the absence of systolic dysfunction on echocardiography (ejection fraction >40% in the previous 12 months). In this selected group of CKD patients, the authors found SA [as defined by an apnoeahypopnoea index (AHI) ≥5/h] in 54.3% of the patients. Almost all of the cases were exclusively obstructive SA. In the whole group (35 patients), AHI correlated weakly with urea levels (r 2 = 0.12) and BMI (r 2 = 0.13), but not with eGFR. In a non-diabetic sub-sample (25 patients), AHI correlated with urea (r 2 = 0.37) and inversely with eGFR (r 2 = 0.25). By design, in both studies a comparison with earlier CKD stages was precluded. The patients studied by us differ from those enrolled in these aforementioned two studies. Firstly, the minimum eGFR in our study was 33 mL/min/1.73 m 2 ; in other words, no patients with CKD stages greater than stage 3 were present. Secondly, no attempts were made to select patients based on comorbidities. In particular, we did not attempt to exclude patients with cardiovascular disease (CVD). Thirdly, the stage 3 CKD patients in our study were older (70.9 years, range 59-82). Since CKD is more frequent in the elderly [19] and CKD patients are plagued by a high burden of CVD, we feel that the patient group studied by us better represents the general CKD population.
In a recent report from the Okinawa Nakamura Clinic Sleep Apnoea Syndrome registry, CKD (defined as an eGFR < 60 mL/min/1.73 m 2 ) was highly prevalent amongst patients with sleep-related breathing disorders (adjusted odds ratio 4.54; 95% CI: 3.92-5.26, P < 0.0001) [20] . Unfortunately, in this study, the frequencies of central, obstructive and mixed apnoeas have not been reported.
Sleep quality has been assessed by means of questionnaires in a few studies in subjects with CKD prior to dialysis [21] [22] [23] . By using the Global Pittsburg Sleep Quality Index (PSQI) score to assess sleep quality in 120 CKD patients (mostly stages 4 and 5), Iliescu et al. [21] found a prevalence of 'poor' sleep (PSQI score > 5) in 53% of the patients. Kurella et al. [22] used the KDQOL-derived sleep quality score in 78 patients with pre-dialysis CKD. Sleep disturbances were seen in 27% with advanced CKD (n = 36; eGFR < 25 mL/min/1.73 m 2 ) and 14% with mild-moderate CKD (N = 42; eGFR >25 mL/min/1.73 m 2 ). De Santo et al. [23] studied a group of 52 newly diagnosed CKD patients and used a 26-item self-administered questionnaire to identify sleep disturbances according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IVTM), criteria. The authors found the prevalence of sleep disorder to be 80.7%. These questionnaire-based studies are highly valuable in delineating subjectively perceived sleep quality but cannot reveal details of sleep pathologies.
Can the high prevalence of central SA (CSA) in stage 3 CKD patients observed in our cohort be explained by gender, age or comorbidities other than CKD? This question was addressed in the multivariate analyses. The association of SA with BMI, smoking status and CHF is well established [4, 24] . Since hypertension and diabetes mellitus are associated with nephropathy, these comorbidities were also included in multiple regression models. Moreover, sleepdisordered breathing has been associated with insulin resistance and glucose intolerance and is frequently found in people with diabetes type 2. CSA is highly prevalent in patients with CHF [4, 25] . The two largest studies involving 450 and 81 patients with CHF reported CSA prevalences of 33% and 40%, respectively [26, 27] . In the present study in univariate analysis, the number of CSA episodes was significantly higher in NYHA class ≥3 patients (7.0 ± 12.8 versus 1.0 ± 2.3 events per hour; P = 0.01 by the MannWhitney test). In multiple regression analysis, both CKD 3 and NYHA class ≥3 were retained as significant predictors of CSA events (Table 3) .
Male gender is another principal risk factor for CSA [25] . In our study, significantly fewer males had CKD 3, arguing against a gender effect. CSA is more common in elderly adults [28] . In univariate analysis, we found a weak correlation between age and CSA (r 2 = 0.03; P = 0.022), but age was not significant in the multiple regression models (Table 3) . Antihypertensive therapy was not predictive of CSA in the univariate and multivariate analysis.
It is tempting to speculate upon why CSA prevalence is increased in CKD stage 3. CSA is thought to be caused by instability of the respiratory control system in which partial carbon dioxide pressure (PCO 2 ) falls transiently and recurrently below the threshold required to stimulate respiratory drive. Hypocapnia is such a destabilizing influence. Heightened ventilatory responsiveness to chemical respiratory stimuli during wakefulness can facilitate respiratory instability, since increased sensitivity of chemoreceptors may contribute to the development of chronic hypocapnia. Tonic activation of excitatory chemoreflex afferents has recently been described in patients with chronic renal failure [29] . A chronically increased ventilatory response to CO 2 results in a PCO 2 close to the apnoea threshold.
Considering the independent association between CKD stage 3 and SA, as well as the results of Iseki [20] , it is tempting to enlarge on the possibility of SA as a cause contributing to CKD. We speculate that hypoxia in the course of apnoea episodes may play a role in the progression of CKD. Firstly, during episodes of apnoea, the drop in systemic blood oxygen saturation results in sympathetic activation, with hypertension being a potential consequence. High blood pressure may in turn contribute to the development of CKD. Secondly, chronic hypoxia may be operative by leading to tubular apoptosis or epithelial-mesenchymal transdifferentiation, which in turn exacerbates fibrosis of the kidney [30] .
Admittedly, our study has limitations, the main being that the patients studied were referred because of a suspected sleep disorder. Therefore, the a priori likelihood of SA was increased. Urinalysis was available only in few patients, preventing us from diagnosing CKD stages 1 and 2. Therefore, we allocated patients to the three groups on the basis of eGFR only. The strength of the study is that no inclusion or exclusion criteria were set with respect to age, gender, comorbidities and concomitant drug therapy. This was done in an attempt to increase the generalizability of our findings.
In summary, our results indicate that SA syndrome, in particular central SA, is associated with an increased prevalence of CKD stage 3. A high level of awareness of the presence of CKD in patients with central SA is warranted to facilitate timely diagnosis, initiate appropriate treatment and potentially improve outcomes.
